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AbstrAct
Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of 
neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate 
the suitability of 99mTc-mercaptoacetyltriglycine (99mTc -MAG3) clearance for the early 
detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was 
measured prior to 128 PRRT cycles (7.6±0.4 GBq 177Lu-octreotate/octreotide each) in 
32 patients. TER reduction during PRRT was corrected for age-related decrease and 
analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate 
(GFR) as measure for renal function was derived from serum creatinine. The mean 
TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 
m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, 
range: -27% to +19%) did not reach significance (p=0.09) but significantly correlated 
with the baseline TER (Spearman p=-0.62, p<0.001). Patients with low baseline TER 
showed an improved TER after PRRT, high decreases were only observed in individuals 
with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-
derived GFR estimates in predicting late nephropathy. TER assessed by 99mTc-MAG3-
clearance prior to and during PRRT is not suitable as early predictor of renal injury 
and an increased risk for late nephropathy.
INtrODUctION
Recent randomized trial results of peptide receptor 
radionuclide therapy (PRRT) in neuroendocrine tumors 
(NET) reporting a significant improvement of progression-
free survival will ultimately result in increasing clinical 
use of PPRT [1]. PRRT is highly effective and usually 
well-tolerated even after repeated treatment cycles [2-4]. 
However, impairment of renal function even years after 
initiation of therapy, especially after treatment with 90Y 
conjugates, may become evident [5]. Generally, a safety 
limit of 23 Gy maximum cumulated absorbed dose to the 
kidneys is assumed [6]. 
Since the kidneys represent the dose-limiting organ 
for PRRT, pre-therapeutic and serial measurements of 
kidney function using laboratory (e.g., serum creatinine 
(SCr)) or imaging tests are mandatory [6]. In daily 
routine, kidney function is usually assessed by estimating 
the Glomerular Filtration Rate (GFR) from the SCr 
concentration although such measurements are affected 
by confounding factors like dietary intake of creatinine 
[7] or presence of comorbidities like hepatic insufficiency 
[8] or glomerulopathy [9]. Based on SCr measurements, 
the decline in renal function after PRRT has been reported 
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to be more pronounced in patients with impaired baseline 
than in patients with preserved renal function [10]. 
However, as the decline of GFR must be at least 50% to 
become evident in patients with initially normal function, 
SCr based GFR estimates (hereafter referred to as eGFR) 
are insensitive to early toxicity [11] and underestimate 
renal impairment in 12% of subjects after PRRT as 
compared to 99mTc-diethylenetriaminepentaacetic acid 
(99mTc- DTPA) clearance measurements [12]. 
It has been suggested that serial assessment of 
renal function by measuring tubular extraction with 
99mTc-mercaptoacetyltriglycine (99mTc-MAG3) or 
orthoiodohippurate might permit earlier and more sensitive 
detection of renal damage [12-14]. Renal irradiation from 
PRRT is most likely to be caused by uptake of radiolabeled 
somatostatin analogues in the proximal tubules where the 
radio-peptide is reabsorbed by the megalin receptor and 
subsequently retained in the interstitium [12, 15]. Hence, 
the tubular extraction might be a superior indicator for 
early stages of kidney affection by PRRT [12, 13]. 
Aiming at an early diagnostic method to identify 
an increased probability of renal impairment, we 
retrospectively analyzed 99mTc- MAG3 clearance data 
to assess the effect of PRRT on the tubular extraction 
rate (TER) and to identify parameters of influence and 
associated risk factors for severe loss of kidney function. 
rEsULts
tubular extraction rate (tEr) prior to and after 
Prrt
The mean TER was 234 ± 53 ml/min/1.73 m² 
at baseline and 221 ± 45 ml/min/1.73 m² at the last 
assessment after a median of 370 days (quantiles: min, 
134 d; 25%, 257 d; 75%, 614 d; max, 915 d). In order 
to correct for the normal decrease of TER with age, 
all measured TER values were normalized to the age-
adjusted lower limit of the normal range (TERLoLi). The 
median ratio TER/ TERLoLi was 1.36 (quantiles: min, 0.92; 
10%, 1.05; 90%, 1.68; max, 2.24) at baseline and 1.27 
(quantiles: min, 0.96; 10%, 1.06; 90%,1.56; max, 2.0) 
after PRRT. Three patients with initially low TER/TERLoLi 
values (0.92, 0.93, and 0.93; age at primary diagnosis, 
63, 70, and 71 y, respectively) showed normalized ratios 
after PRRT (1.08, 1.05, and 1.11, respectively). All three 
patients took nephrotoxic medication regularly and two of 
them underwent chemotherapy prior to PRRT and suffered 
from diabetes and arterial hypertension. 
Normalized to the baseline ratios, the final mean 
value of TER/TERLoLi was reduced in the entire cohort to 
97% (95% confidence interval of the mean, 92%-102%; 
standard deviation, 14%). The trend towards reduced renal 
function did not reach statistical significance (p = 0.09; 
Wilcoxon test). The relative change of the ratio TER/
TERLoLi from baseline to the last measurement ranged 
from -27% to +19% (Figure 1) with 21 patients showing 
a decreased and 11 an improved TER-ratio. Loss of TER 
was significantly related to the baseline TER (Spearman ρ 
= -0.62; p < 0.001) but not to the cumulative activities Acum, 
the number of treatment cycles, the treatment duration, the 
patient age, prior chemotherapy, hypertension, diabetes 
mellitus, antihypertensive medication, intake of analgesics 
or somatostatin analogues (Table 1).
Four patients under furosemide intake showed an 
increase of TER/TERLoLi to 111% ± 4% of the initial value 
which was higher than in the rest of the cohort (p = 0.02; 
T-test). One patient presented a decrease of TER/TERLoLi 
under the lower normal limit during therapy from 1.19 to 
0.96.
regression analyses
In order to demonstrate the dependence of the 
change of TER/TERLoLi per administered activity in 
GBq as a function of TER/TERLoLi prior to first therapy, 
regression analyses of TER/TERLoLi vs. administered 
activities was performed (Figure 2). The change of 
TER/TERLoLi per GBq 
177Lu-DOTATATE/-TOC was 
significantly correlated to the initial renal function 
(Spearman ρ = -0.62; p < 0.001). 
tEr and kidney uptake
Twenty-five of the 32 patients had single photon 
emission computed tomography/computed tomography 
(SPECT/CT)data acquired at 24 h after the activity 
administration in at least 2 treatment cycles. The uptake 
per ml of kidney parenchyma increased with decreasing 
ratio TER/TERLoLi (ρ = -0.24; p = 0.01; Spearman; 
Supplementary Figure 1a). Loss of TER in the course of 
treatments was associated with increasing kidney uptake 
as assessed by intra-individual mean change of uptake 
per ml of kidney parenchyma from treatment cycle to 
treatment cycle as a function of the change of TER (ρ = 
-0.43; p < 0.03; Spearman; Supplementary Figure 1b).
Estimated GFr (eGFr) prior to and after Prrt
The mean eGFR was 92 ± 25 ml/min/1.73 m² prior 
to PRRT and 90 ± 22 ml/min/1.73 m² at the end of the 
last treatment cycle; the reduction was not statistically 
significant (ρ = 0.48; paired samples T-test). At the end 
of therapy, eGFR was higher in 15, lower in 14, and 
unchanged in 3 individuals. Change of eGFR during 
treatment was significantly correlated to the initial renal 
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function (Spearman ρ = -0.38; p = 0.03; Figure 1c). More 
than 10% loss of eGFR was only observed in patients 
with good renal function ( > 90 ml/min/1.73 m²). The 
correlation observed between the change of eGFR and the 
change of TER/TERLoLi during PRRT was not significant 
(table 1). 
As compared to the measurements at the end of 
treatment, the eGFR was significantly reduced to 78 ± 34 
ml/min/1.73 m² (p = 0.01; paired samples T-test) in follow-
up measurements of the serum creatinine performed in 27 
of the 32 patients at a median of 837 days after the PRRT 
initiation (quantiles: min, 158 d; 25%, 632 d; 75%, 955 
d; max, 1825 d). Follow-up eGFR data were lower in 20, 
unchanged in 1, and higher in 6 individuals. According 
to the Common Terminology Criteria for Adverse Events 
(CTCAE) 4.0, grade 2 toxicity was observed in 5 of the 
27 patients (18.5%). One individual with reduced eGFR 
prior to (58 ml/min/1.73 m², TER/TERLoLi: 0.93) and after 
(52 ml/min/1.73 m², TER/TERLoLi: 1.05) three treatment 
cycles (total 17.9 GBq 177Lu-DOTATATE/-TOC) showed 
grade 3 toxicity (1/27, 3.7%) at follow-up 1818 days after 
start of PRRT. This patient did not receive any additional 
therapy after PRRT nor experienced disease progression 
within follow-up. However, a potential nephrotoxic 
chemotherapy regimen including cisplatin and fluorouracil 
prior to PRRT was performed. The change of TER during 
PRRT was not predictive for late kidney failure (Figure 
1d). 
The relative loss of eGFR during follow-up after 
PRRT correlated better with the pre-therapeutic eGFR 
(Spearman ρ = 0.61; p = 0.001) than with the pre-
therapeutic TER/TERLoLi ratio (Spearman ρ = 0.38; p = 
0.05). No correlation was observed with the change of 
TER/TERLoLi (Spearman ρ = -0.16; p = 0.42, Figure 1d) 
Table 1: Significance of clinical parameters on the change of TER/TERLoLi during Prrt.
clinical parameters ρ p
Baseline TER -0.62 <0.001 Spearman
Change of glomerular filtration rate
during PRRT





Cumulative activities, Acum -0.21 0.25
Number of treatment cycles -0.09 0.61
Treatment duration* -0.05 0.81
Patient age 0.08 0.65




Intake of analgesics 0.46
Somatostatin analogues 0.36
Furosemide intake (4 of 32 patients) 0.02
*Treatment duration = time span between first PRRT cycle and last TER measurement. TER = tubular extraction rate, TER/
TERLoLi = TER normalized to the lower normal limit TERLoLi, PRRT = Peptide Receptor Radionuclide Therapy.
Spearman’s ρ was calculated to test for statistical dependence on a variable, Student’s t-test was used to compare groups.
Table 2: Patients’ characteristics 
Characteristic Number of patients (%)
Sex female male










 9/32  (28.1)
 2/32  (6.25)
 2/32  (6.25)
 2/32  (6.25)




surgery of the primary, transarterial chemoembolization
13/32 (40.6)







  6/32 (18.8)
16/32 (50)
* analgetics, antihypertensive medication, lipid-lowering medication, furosemide intake.
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and the change of eGFR (Spearman ρ = -0.28; p = 0.16) 
during PRRT.
Twenty of the patients with eGFR follow-up 
had SPECT/CT data acquired at 24 h after the activity 
administration in at least 2 treatment cycles. The relative 
loss of eGFR during follow-up was not associated with the 
mean kidney uptake in these patients (ρ = -0.06; p < 0.79; 
Spearman; Supplementary Figure 1c).
In this cohort, pre-therapeutic TER data were 
inferior to GFR estimates based on plasma creatinine in 
predicting radiation-induced nephropathy after PRRT. The 
change of TER during PRRT was not predictive for late 
toxicity. 
DIscUssION
This is the first study to assess PRRT-induced renal 
toxicity by serial 99mTc-MAG3 clearance measurements. 
A mean TER loss of 3% between the first and the last 
assessment was recorded. This decline in kidney function 
is lower than previously reported for creatinine clearance 
with Gupta et al. reporting a significant decrease of 24% 
in GFR and a major increase in SCr after 177Lu-octreotate 
[10]. Valkema et al. demonstrated GFR reductions of 4-7% 
per year for 177Lu-octreotate and 90Y-octreotide [16]. Also 
investigating GFR but measuring GFR more accurately 
by use of 99mTc-DTPA, Sabet et al. observed minor renal 
impairment in 43% of the cohort and serious renal adverse 
effects occurring in only 1.3% after 177Lu-octreotate 
Figure 1: Relative change of the tubular extraction rate (TER) normalized to the lower normal limit TERLoLi between 
the first and last clearance measurements as a function of a. the cumulated activity (Spearman ρ = -0.21; p = 0.25) and b. the 
ratio TER/TERLoLi prior to Peptide Receptor Radionuclide Therapy (PRRT) (Spearman ρ = -0.62; p < 0.001) as well as c. relative change 
of estimated glomerular filtration rate (eGFR) during treatment as a function of the renal function prior to PRRT (Spearman ρ = -0.38; p = 
0.03) and d. the change of eGFR in the follow-up of 27 patients as a function of the change of TER/TERLoLi during PRRT (Spearman ρ = 
-0.16; p = 0.42). The lines indicating linear regressions were drawn to guide the eyes.
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Figure 2: Dependence of the change of tubular extraction rate TER/TERLoLi per administered activity in Gbq as a 
function of TER/TERLoLi prior to first therapy. Each data point with error bars represents the result of a regression analysis as 
illustrated in Figure 3 with the correspondent uncertainty of the regression parameters. Small error bars indicate a clear trend of TER/
TERLoLi with minor scatter of data. The result of a weighted linear regression to the data is shown by a straight line characterized by intercept 
1.08% ± 0.27% and slope -0.89% ± 0.20%. Individuals with typical renal clearance  TER-1.43 TERLoLi are expected to have a relative loss 
of TER of 0.20% per GBq [177Lu-DOTA(0),Tyr(3)]-octreotate/octreotide (177Lu-DOTATATE/-TOC) or 1.4% per treatment cycle with a 
standard activity of 7.5 GBq 177Lu-DOTATATE/-TOC. TER = tubular extraction rate, TER/TERLoLi = TER normalized to the lower normal 
limit TERLoLi, PRRT = Peptide Receptor Radionuclide Therapy.
Figure 3: Tubular extraction rate (TER) normalized to the lower normal limit (TERLoLi) vs. the cumulated activity (Acum) in 
a patient with improving renal function in the course of 4 cycles of Peptide Receptor Radionuclide Therapy (dots) and a patient with loss 
of function during 8 cycles (circles). The dashed lines show the results of linear regression: TER/TERLoLi = ß0+ß1*Acum [GBq] (ß0: 90.1% 
± 2.3% and 132.7% ± 2.7%; ß1: 0.50% ± 0.12% and -0.51% ± 0.07% per GBq, respectively). TER/TERLoLi is 1 or larger in patients with 
normal kidney function and < 1 in those with impaired TER.
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therapies [12]. The yearly loss of GFR reported by Sabet et 
al. of 2% is similar to our findings of an age-corrected loss 
of TER of 3%. As in the present study, clinical parameters 
like patient age, prior chemotherapy, diabetes mellitus, 
antihypertensive medication or cumulated administered 
activity have reported not to be associated with loss of 
function [12]. 
However, the most remarkable observation was 
the significant dependence of TER reduction on the renal 
function prior to therapy: only patients with initially high 
clearance showed a considerable loss of TER. In contrast, 
patients with low TER experienced no further decrease. 
In line with our findings, Garske et al. also observed the 
same phenomenon of improvement of renal function 
under PRRT and therefore recommended to estimate 
kidney function from more than one test to avoid false 
positive results. The reason for this observed improvement 
is not totally clear: It was hypothesized that the GFR 
improvement could also be seen in the light of better 
urinary flow due to reduced tumor burden in the case of 
shrinkage [17]. However, none of the investigated patients 
in our study experienced a significant reduction of tumor 
mass.
Neither the cumulative activities were decisive for 
TER reduction in our cohort (data not shown) nor was 
higher activity uptake in the kidneys associated with 
higher loss of TER. On the contrary, a significant negative 
correlation was observable between MAG3 clearance 
and renal uptake at 24 h after activity administration. A 
similar correlation has recently been found by Svensson 
et al. who reported that renal absorbed doses appeared to 
be higher in patients with baseline impaired renal function 
[18]. Interestingly, loss of eGFR in the follow-up was not 
associated with kidney uptake during therapy.
Although dose estimates deduced from the SPECT/
CT uptake data of our patients and the mean half-life 
reported by Garske et al. [19] suggest that all but one 
patient remained below the safety limit of 23 Gy kidney 
absorbed dose, late GFR follow-up measurements 
revealed grade 2/3 toxicity in 6 of 27 (22.2%) patients. 
This finding is in line with a study including 290 patients 
after 177Lu-based PRRT which detected grade 1/2 renal 
toxicity in 25.5% [20]. It should, however, be noted 
that our data cannot be used to demonstrate the toxicity 
of PRRT with 177Lu because most of the patients in our 
cohort received other potentially nephrotoxic treatment as 
well. Late clinical manifestation of renal toxicity was not 
related to loss of TER during PRRT but correlated with 
renal function prior to therapy. The eGFR prior to therapy, 
although deduced from SCr measurements only, correlated 
better with the relative loss of eGFR after PRRT than 
the TER prior to treatment. The 99mTc-MAG3 clearance 
assessments performed in our patients prior to and during 
PRRT demonstrated only minor loss of renal function 
during PRRT, an observation which was supported by 
the minor changes of eGFR observed during treatment. 
Relevant information was not gained from the TER 
measurements which were unsuitable as early diagnostics 
to identify an increased probability of later renal failure. 
Moreover, blood-based GFR estimation of kidney function 
has the advantage of being more simple, rapid and less 
expensive as compared to 99mTc-MAG3 studies. 
This study has some limitations. After the last 
TER assessment, 13 patients (40%) received another 
treatment cycle which might have also influenced renal 
function during long-term follow-up. The statistical power 
is limited by the small patient number, the retrospective 
nature of the analysis, and the lack of information on the 
effective half-lives of the activity in the kidneys preventing 
reliable assessments of the renal absorbed doses. A 
prospective study including full kidney dosimetry and a 
larger cohort with more patients with renal impairment 
is desirable to strengthen our preliminary findings. 
Furthermore, other assessments of tubular function, such 
as alpha-1 microglobulin (urine), and direct comparison to 
exactly measured glomerular function e.g. by 99mTc-DTPA 




Since this study comprised the retrospective analysis 
of routinely acquired data, the local ethics committee 
waived the need for further approval. All patients 
gave written informed consent for the recording and 
anonymized analysis of their data.
Patient cohort
Thirty-two patients (7 female, 25 male) with 
histologically proven advanced NET who underwent 
PRRT at our institution between April 2010 and July 2014 
were retrospectively analyzed. Patients received at least 3 
PRRT treatment cycles up to July 2015. Except 2 young 
patients (aged 24 and 30 years, respectively), the mean 
age of included patients at start of therapy was 64.7 ± 9.0 
years. All patients gave written informed consent to the 
therapeutic and diagnostic procedures. Detailed patient 
information is provided in Table 2. Prior to the first PRRT 
cycle, somatostatin receptor-directed positron emission 
tomography (PET) was performed to prove receptor 
expression by the tumor in each individual. The general 
exclusion criteria, as defined by the Joint IAEA, EANM, 
and SNMMI practical guidance, were applied [6]. Kidney 
function measurements prior to each PRRT cycle were 
performed to verify the TER to be at least 60% of the mean 
age-adjusted normal value. Pre-existing risk factors for the 
occurrence of kidney toxicity such as diabetes mellitus 
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(n = 6), arterial hypertension (n = 13), nephrotoxic drug 
intake, long-term use of analgetics, antihypertensive, 
furosemide and lipid-lowering medication (n = 16) were 
recorded. 
Assessment of kidney function
Prior to each treatment cycle, all patients underwent 
(as part of clinical routine work-up) renal scintigraphy 
with 99mTc-labelled MAG3 on a single head gamma camera 
(Signature; Siemens, Erlangen, Germany) equipped with a 
medium-energy, high-resolution collimator as previously 
described [21]. TER was assessed from measured activity 
concentrations in plasma samples corrected for the body 
surface according to the single sample method introduced 
by Bubeck et al. [22]. Clearance values deduced from 
samples taken after 20 and 30 min after the 99mTc-MAG3 
administration were averaged to minimize errors. Age-
adjusted mean normal values TERNorm were calculated 
according to the formula: TERNorm = (435 - 3.03 x age (y)) 
ml/min/1.73m2 with the lower limit of the normal range: 
TERLoLi = 70% TERNorm [23]. 
During and after treatment, serum creatinine (SCr) 
was measured periodically and the glomerular filtration 
rate glomerular filtration rate (eGFR) was calculated by 
the CKD-EPI equation taking age, ethnicity, and weight 
into account [24]. 
treatment
All patients treated by PRRT complied with the 
requirement TER> 60% TERNorm as recommended in the 
guideline [6]. The patients were hospitalized for 3 days 
starting 1 day prior to therapy to guarantee adequate 
hydration (1 l saline/day). The radiopharmaceutical, 
[177Lu-DOTA(0),Tyr(3)]-octreotate/octreotide (177Lu-
DOTATATE/-TOC; 177Lu delivered by ITG, Munich, 
Germany), was prepared as previously reported [25] 
and infused over 20-30 minutes with a specific activity 
of 100-150 GBq/µmol. For kidney protection, a solution 
containing 25 g of lysine and 25 g of arginine diluted 
in 2 l of normal saline was infused over 4 h, starting 1 
h before PRRT [6]. In total, 32 patients received 128 
treatment cycles (2, 3, 4, 5, 6, 7, and 8 cycles in 5, 9, 
10, 3, 1, 2, and 2 patients, respectively) with subsequent 
TER evaluation. After the last TER assessment, 13 of 
the patients received another treatment cycle without 
following MAG3 clearance assessment. 124 treatment 
cycles included in the analysis were performed with 
standard activities of 7.6±0.4 GBq 177Lu-DOTATATE/-
TOC. One patient with slightly decreased renal function 
of TER- 65% TERNorm was treated twice with reduced 
activities of 5.2 and 5.5 GBq 177Lu-DOTATATE. The 
last cycle of this patient (7.2 GBq 177Lu-DOTATATE) 
without subsequent TER assessment was excluded from 
TER analysis. Another patient with TER = 109% TERNorm 
received two compassionate use treatment cycles with 
activities of 19.3 and 17.3 GBq 177Lu-DOTATOC and an 
unconsidered last cycle with 8.1 GBq 177Lu-DOTATOC 
(without subsequent TER assessment). The median time 
interval between treatment cycles was 91 days (range: 63 
- 830 d; 1st quartile: 84 d, 3rd quartile: 112 d).
An exact assessment of kidney absorbed doses from 
therapy was not possible because serial images necessary 
to determine the effective half-life in the organ had not 
been acquired. However, SPECT/CT of the abdomen was 
performed 24 h (n = 101) or 2 to 5 days (n = 18) after 
activity administration in 119/128 treatment cycles. All 
SPECT/CT images were acquired using the same double 
head gamma camera (Siemens Symbia T2; Siemens, 
Erlangen, Germany) equipped with medium energy 
collimators calibrated by phantom measurements with 
177Lu activity standards (sensitivity, sum of both heads: 28 
counts per second per MBq 177Lu in a 15% window at 208 
keV). Data were reconstructed using a 3D Ordered Subsets 
Expectation-Maximization (OSEM, 6 subsets, 6 iterations, 
Gauss 6 mm) algorithm with corrections for scatter and 
attenuation to obtain absolute activity quantification in 
voxels sized 0.11 cm³. 
Data evaluation
To identify parameters influencing TER, all TER 
data deduced from 99mTc-MAG3 clearance measurements 
were normalized to the lower limit of normal range by 
calculating the ratio TER/TERLoLi. This method corrects 
for the normal decrease of renal function with age in the 
course of treatment for the individual patient and makes 
data from individuals of different ages comparable. The 
ratio TER/TERLoLi is 1 or larger in patients with normal 
kidney function, < 1 in those with impaired TER, and 
is expected to equal 1/70% = 1.43 in individuals with a 
typical renal clearance TERNorm matching the mean age-
adjusted normal value.
The time course of TER/TERLoLi was analyzed 
for each patient by comparing the MAG3 clearance 
data measured at baseline and after the last PRRT cycle 
and relating the change of TER/TERLoLi to the activities 
administered between both assessments of renal function. 
As explained above, data from the last PRRT cycle without 
later TER measurement were omitted from analysis. 
In a more complex evaluation, regression analyses 
including all TER measurements as a function of the 
previous administered activities were performed for 
each individual. Examples of linear regressions of TER/
TERLoLi vs. the cumulated activities Acum (TER/TERLoLi = 
ß0+ß1*Acum [GBq]) are shown in Figure 3. The coefficient 
ß0 represents a fit estimate of TER/TERLoLi prior to the first 
PRRT, ß1 the absolute change, and ß1/ß0 the relative change 
of TER/TERLoLi per GBq administered activity. The 
uncertainties of the coefficients, ∆ß0 and ∆ß1, respectively, 
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indicate the scatter of the measured TER values. 
To determine the dependence of the relative change 
of TER/TERLoLi on the initial value of TER/TERLoLi prior 
to PRRT, the values of ß1/ß0 were calculated for each 
individual as a function of the corresponding ß0 assuming 
uncertainties ∆ß1/ß0 and ∆ß0/ß0, respectively, and a 
weighted linear regression was performed.
statistical analysis
Statistical analysis was performed using IBM SPSS 
(version 23.0, Ehningen, Germany). Data were analyzed 
with non-parametric tests when the Shapiro-Wilk test 
indicated incompatibility with normal distribution. 
Spearman’s rank correlation coefficient was calculated 
to test for statistical dependence between two variables. 
Quantitative values were reported as mean ± standard 
deviation or median and quantiles as appropriate. The tests 
used are reported together with the results. All statistical 
tests were performed two-sided and a p-value < 0.05 was 
considered to indicate statistical significance. 
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